EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Relationship of dihydroergotamine pharmacokinetics, clinical efficacy, and nausea—A narrative review

Richard B Lipton, John A Kollins, Detlef Albrecht iD

Headache: The Journal of Head and Face Pain · 2025

DOI: 10.1111/head.14877 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Headache: The Journal of Head and Face Pain, 2025. Verfasst von Richard B Lipton und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Albert Einstein College of Medicine, and Montefiore Medical Center, Bronx, New York, USA. Hauptthemen laut MEDLINE: Dihydroergotamine, Nausea, Migraine Disorders, Analgesics, Non-Narcotic. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Satsuma Pharmaceuticals, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To assess the relationships between dihydroergotamine (DHE) pharmacokinetic (PK) parameters, clinical efficacy, and nausea incidence to determine a DHE PK profile that optimizes efficacy while minimizing adverse events (AEs), particularly nausea.

Background

Dihydroergotamine is a widely used option for the acute treatment of migraine. Although multiple DHE dosage forms, with varying PK and AE profiles, have been evaluated in randomized controlled trials (RCTs), the relationships between PK profile, efficacy, and the common DHE‐related AE, nausea, have not been comprehensively evaluated.

Methods

A literature search identified RCTs evaluating the efficacy (2‐h pain relief [2hPR]) of different DHE dosage forms. The PK profiles for these DHE dosage forms were determined from published literature. Univariate regression analyses were performed to determine the PK parameters that best predicted 2hPR across DHE dosage forms. The relationship between maximum plasma concentration ( C max ) and nausea incidence for various dosage forms was determined from published Phase 1 trials.

Results

The literature search identified nine RCTs with DHE dosage forms that reported 2hPR: DHE liquid nasal spray (four studies), DHE administered subcutaneously (three), and DHE administered via oral pulmonary inhalation (two). The DHE PK parameters that best predicted 2hPR rates were C max and area under the curve from time zero to 0.5 h post‐dose (AUC 0‐0.5h ) ( R 2 = 0.59 for each). Across Phase 1 trials, nausea incidence was minimal when C max was

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DihydroergotamineNauseaMigraine DisordersAnalgesics, Non-NarcoticHumansRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

2‐h pain reliefdihydroergotaminemigrainenauseapharmacokinetics

Substanzen

DihydroergotamineAnalgesics, Non-Narcotic

Autor:innen und Institutionen

  • Department of Neurology, Albert Einstein College of Medicine, and Montefiore Medical Center, Bronx, New York, USA.
  • Department of Epidemiology and Population Health, Albert Einstein College of Medicine, and Montefiore Medical Center, Bronx, New York, USA.
  • Satsuma Pharmaceuticals, Inc., Durham, North Carolina, USA.

ORCID-Profile: Detlef Albrecht

Förderung

  • Satsuma Pharmaceuticals, Inc.

Zitieren

APA

Lipton, R. B., Kollins, J. A., & Albrecht, D. (2025). Relationship of dihydroergotamine pharmacokinetics, clinical efficacy, and nausea—A narrative review. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14877

Vancouver

Lipton RB, Kollins JA, Albrecht D. Relationship of dihydroergotamine pharmacokinetics, clinical efficacy, and nausea—A narrative review. Headache: The Journal of Head and Face Pain. 2025. doi:10.1111/head.14877

BibTeX
@article{Lipton2025,
  author = {Lipton, Richard B and Kollins, John A and Albrecht, Detlef},
  title = {Relationship of dihydroergotamine pharmacokinetics, clinical efficacy, and nausea—A narrative review},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2025},
  doi = {10.1111/head.14877}
}
Kostenlos starten →